“
TL;DR
The central conclusion is that Bruch's membrane barrier function is a critical, underappreciated factor for achieving effective therapeutic delivery of complement inhibitors to the retina.
Journal of Clinical Medicine · 8 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central conclusion is that Bruch's membrane barrier function is a critical, underappreciated factor for achieving effective therapeutic delivery of complement inhibitors to the retina.
This narrative review synthesises evidence on Bruch's membrane structure, age-related changes, complement dysregulation in AMD pathogenesis, and therapeutic delivery strategies for complement inhibitors. A potential emergent adverse event of intravitreal complement inhibitors—macular neovascularisation—is highlighted as an unresolved safety concern. The review concludes that further research on complement diffusion across BrM and optimisation of therapeutic delivery routes is needed.